Literature DB >> 21080791

Estrogen-free oral hormonal contraception: benefits of the progestin-only pill.

Nilson Roberto de Melo1.   

Abstract

Although combined oral contraceptives (COCs) are commonly used and highly effective in preventing pregnancy, they may not be suitable for some women. COC use is associated with increased rates of cardiovascular events and is not recommended in nonbreastfeeding women in the immediate postpartum period or in breastfeeding women during the initial 6 months of breastfeeding. Moreover, estrogen-related adverse effects, such as headache, are common. Estrogen-free progestin-only pills (POPs) are a valuable option in women who prefer to take an oral hormonal contraceptive, but are ineligible for, or choose not to use, COCs. Although some POPs have been associated with lower contraceptive effectiveness than COCs, the POP containing desogestrel has shown similar contraceptive effectiveness to COCs. The most commonly reported complaints in women using all POPs are bleeding problems. Counseling women interested in using POPs about the variable bleeding patterns associated with this method may improve compliance and acceptance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21080791     DOI: 10.2217/whe.10.36

Source DB:  PubMed          Journal:  Womens Health (Lond)        ISSN: 1745-5057


  3 in total

1.  Progestin-only contraceptive pill use among women in the United States.

Authors:  Kelli Stidham Hall; James Trussell; Eleanor Bimla Schwarz
Journal:  Contraception       Date:  2012-06-06       Impact factor: 3.375

Review 2.  Progestin and breast cancer risk: a systematic review.

Authors:  Marsha Samson; Nancy Porter; Olubunmi Orekoya; James R Hebert; Swann Arp Adams; Charles L Bennett; Susan E Steck
Journal:  Breast Cancer Res Treat       Date:  2015-12-23       Impact factor: 4.872

Review 3.  Efficacy of Low-Dose Estrogen-Progestins and Progestins in Japanese Women with Dysmenorrhea: A Systematic Review and Network Meta-analysis.

Authors:  Masaru Iwata; Yoshihiro Oikawa; Yutaka Shimizu; Naotaka Sakashita; Ayako Shoji; Ataru Igarashi; Yutaka Osuga
Journal:  Adv Ther       Date:  2022-09-01       Impact factor: 4.070

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.